Benchmark Electronics enters its Q2 results — reported after the close on July 29 — having already shed 16% over the past month, with insiders having sold heavily near the highs and options traders now running their most call-heavy tilt in a year.
The insider story here is the most telling. Through May and June, a cluster of senior executives sold into strength: the Chairman cleared nearly $2 million at $85, a Director topped $1.97 million at $81.49, the CEO sold $1.1 million at $87.57, and the CLO added another $1.73 million at $86.25. All of this happened while the stock was trading 10–15% above where it closed this week at $76.93. Net insider selling over the past 90 days totals approximately $7.3 million. These weren't small option exercises — the Chairman and Director transactions each carry a significance score of 3, the highest in recent history for this name. That level of coordinated selling at the highs is a data point the market is clearly now digesting.
The borrow market tells a strikingly relaxed story. Availability — the ratio of shares still lendable versus shares already borrowed — has actually loosened sharply this week, rising to over 7,000%, well above the 52-week low of around 1,590%. Short interest has simultaneously fallen 12% over the past week, easing to roughly 3.9% of the free float. Borrowing costs are essentially nominal at 0.46%. This is not a stock under any meaningful short pressure: availability is deep, costs are trivial, and short interest has been trimmed rather than built into the decline. The ORTEX short score has drifted lower all week, from 38.2 to 35.7 — a mild and falling reading, not an escalating one.
Options positioning is the sharpest contra-signal in the setup. The put/call ratio has dropped to 0.054, the lowest level of the past year and well below its 20-day average of 0.077. That puts the z-score at –1.34, meaning call demand is running unusually heavy relative to recent norms. One interpretation: some traders were positioned for a post-earnings bounce rather than hedging against further downside. The 52-week high on the PCR was 1.84 — the current reading is barely a fraction of that, suggesting no meaningful defensive hedging has been put on ahead of the print.
The Street has been quiet since April 30, when Needham raised its target to $80 following the prior quarter's blowout result — a print that sent the stock up 19% in one day and 26% over the subsequent five sessions. With the consensus sitting at a solitary Buy rating and a $78 mean target now effectively in line with the current price of $76.93, analyst support provides little incremental lift. The forward EPS growth factor ranks in the 84th percentile — genuinely strong — while the EPS surprise rank (28th percentile) and 30-day EPS momentum (31st percentile) are more pedestrian. The PE multiple has compressed roughly 6 points over the past month to 26x, tracking the price decline rather than reflecting any earnings revision. Peer context reinforces the sector-wide pressure: SANM fell 21% on the week and TTMI dropped 26%, while PLXS and JBL shed 4–5%. BHE's 9% weekly decline looks relatively contained by comparison, but the sector is clearly under stress.
The key watch for this note is whether today's Q2 print delivers another earnings beat of the scale that drove April's rally — and whether management guidance is strong enough to reverse the narrative that insider selling near $85–$88 was well-timed.
See the live data behind this article on ORTEX.
Open BHE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
